Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us
Irinotecan (SN-38) is a potent and broad-spectrum anticancer drug that targets DNA topoisomerase I (Top1). It exerts its cytotoxic effects by binding to the Top1-DNA complex and preventing the re-ligation of the DNA strand, leading to the formation of lethal DNA breaks. Following the initial respons...
Main Authors: | Santosh Kumar, Michael Y. Sherman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/8/7233 |
Similar Items
-
Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors
by: Jung Yoon Jang, et al.
Published: (2023-05-01) -
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
by: Victor M. Matias-Barrios, et al.
Published: (2023-01-01) -
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
by: Mateusz Kciuk, et al.
Published: (2020-07-01) -
Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks
by: Santosh Kumar, et al.
Published: (2023-05-01) -
The role of autophagy in DNA damage
by: Trugenberger, C
Published: (2023)